{"id":"W3087872591","doi":"10.1016/j.annonc.2020.08.882","title":"623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; Daiichi Sankyo Europe; Pharmacyclics; Merck Sharp and Dohme; Genentech; EMD Serono; MorphoSys; PharmaMar; Astellas Pharma; Eisai; Pfizer; Incyte; BeiGene; Menarini Silicon Biosystems; Beth Israel Deaconess Medical Center; Astex Pharmaceuticals; Valeant Pharmaceuticals International; Advanced Accelerator Applications; Endocyte; Sierra Oncology; Genomic Health; Ipsen; Array BioPharma; Daiichi-Sankyo; Teva Pharmaceutical Industries; Exelixis; Sanofi; Merck; GlaxoSmithKline; Amgen; Jounce Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Internal medicine; Docetaxel; Oncology; Abiraterone; Chemotherapy; Cancer; Immunotherapy; Androgen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002084488,0.0007420018,0.001286623,0.0004740472,0.0002934257,0.001437047,0.001367221,0.001185337,0.01016191],"category_scores_gemma":[0.001542485,0.0004115712,0.001519384,0.0005581526,0.0002568036,0.0006769245,0.00040111,0.00296418,0.002878895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001160226,"about_ca_system_score_gemma":0.002048302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003485085,"about_ca_topic_score_gemma":0.01514337,"domain_scores_codex":[0.9996997,0.0001030741,0.00001984752,0.00003648881,0.0000914351,0.00004943324],"domain_scores_gemma":[0.9992994,0.0001860907,0.0001287324,0.00003942583,0.0001429185,0.0002033803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.05181294,0.005105939,0.004101163,0.003181752,0.002961004,0.0003030297,0.0001290959,0.001767805,0.01637108,0.001362205,0.1621958,0.7507082],"study_design_scores_gemma":[0.2326766,0.08531444,0.0490909,0.002152919,0.007369631,0.001650387,0.0001438138,0.002827481,0.006511607,0.002643442,0.6094759,0.0001429155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.339798,0.3004192,0.01208608,0.0396074,0.008224521,0.01335431,0.08995827,0.002128875,0.1944235],"genre_scores_gemma":[0.5229143,0.2173298,0.02914604,0.05067338,0.003340261,0.008055259,0.08850726,0.000732271,0.07930142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01016191,"threshold_uncertainty_score":0.03399497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1420630183329399,"score_gpt":0.4476406662763026,"score_spread":0.3055776479433627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}